- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07928167
Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients
A Randomized Phase 2 Trial of Lenvatinib Plus Pembrolizumab With or Without Stereotactic Radiation Therapy in Patients With Clear-cell Metastatic Renal Cell Carcinoma, Low Tumor Burden, and Stable Disease.
Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenvatinib and pembrolizumab.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Metastatic clear cell renal cell carcinoma (mRCC) is sensitive to combination of lenvatinib and pembrolizumab. The CLEAR study showed positive results in patients with low tumor burden. However, around 20% of patients do not respond and have stable disease. In the VOLGA study, we demonstrated better outcomes in patients with irradiation of even a single lesion during targeted therapy. Thus, investigators hypothesize that stereotactic radiotherapy (SBRT) to multiple lesions in patients undergoing ongoing therapy with pembrolizumab and lenvatinib will increase the objective response rate, which may correlate with improved overall survival.
LASER is a randomized multicenter phase 2 study. Initially, all patients with histologically confirmed mRCC, the median sum of the diameters of target lesions ≥ 7 cm, ECOG 0-2, and the absence of prior systemic therapy for metastatic disease will receive a 12-week induction with lenvatinib and pembrolizumab, followed by radiological assessment according to RECIST 1.1 and allocation by outcome (response, stable disease, or disease progression). Patients with stable disease (SD) will be randomized in a 1:1 ratio into two groups: 1) lenvatinib + pembrolizumab + SBRT (N=27) or 2) lenvatinib + pembrolizumab alone (N=27). In the SBRT group, the choice of target for irradiation - up to 3 (three) lesions - is determined by a multidisciplinary team. The primary endpoint is the objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease (assessed every 12 weeks according to RECIST 1.1). The statistical hypothesis is based on an expected ORR of 15% in the control group versus 50% in the SBRT group. A two-sided α of 0.05 and a power of 80% require 27 patients in each group (54 randomized). The total enrollment will be 150 patients.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Ilya Tsimafeyeu
- Telefonnummer: +74999054690
- E-mail: sten_to@mail.ru
Studiesteder
-
-
-
Kazan', Rusland, 420000
- Rekruttering
- Republican Dispensary of Tatarstan
-
Kontakt:
- Milyausha Mukhitova
- Telefonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Moscow, Rusland, 115478
- Rekruttering
- N.N. Blokhin National Medical Research Center of Oncology
-
Kontakt:
- Petr Bulychkin
- Telefonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Moscow, Rusland, 125630
- Rekruttering
- STOONCO clinic
-
Kontakt:
- Valentina Leonenko
- Telefonnummer: +7 (915) 809-03-03
- E-mail: bucare@bucare.org
-
Orenburg, Rusland, 460000
- Rekruttering
- Orenburg Regional Cancer Center
-
Kontakt:
- Makhabbat Murzalina
- Telefonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Saint Petersburg, Rusland, 194291
- Rekruttering
- SBHI Leningrad Regional Clinical Hospital
-
Kontakt:
- Andrey Lebedinets
- Telefonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Tyumen, Rusland, 625000
- Rekruttering
- Cancer Center "Medical City"
-
Kontakt:
- Vera Peryshkina
- Telefonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Ufa, Rusland, 450000
- Rekruttering
- Republican Clinical Oncology Dispensary
-
Kontakt:
- Alexander Sultanbaev
- Telefonnummer: +7 (347) 216-3671
- E-mail: ufa.rkod@doctorrb.ru
-
Ulyanovsk, Rusland, 432000
- Rekruttering
- "ErSpace" Radiation Therapy Center
-
Kontakt:
- Natalia Dengina
- Telefonnummer: +78422737472
- E-mail: info@rspei.ru
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically confirmed clear-cell renal cell carcinoma.
- Presence of measurable lesions per RECIST 1.1.
- Sum of diameters of target lesions ≤ 7 cm.
- ECOG 0-2.
- No prior systemic therapy for metastatic disease.
Exclusion Criteria:
- Uncontrolled comorbidities that preclude the use of TKI/IO or SBRT.
- Prior SBRT to the lesions planned for irradiation, rendering re-irradiation unsafe.
- Active autoimmune diseases requiring systemic immunosuppressants.
- Symptomatic CNS metastases (patients with asymptomatic metastases may be included).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Lenvatinib + Pembrolizumab + SBRT
|
20 mg orally once daily. 200 mg intravenously every 3 weeks The dosage regimen is determined by a radiation oncologist and depends on the location of the lesion. |
|
Aktiv komparator: Lenvatinib + Pembrolizumab
|
20 mg orally once daily. 200 mg intravenously every 3 weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Response of unirradiated lesions according to RECIST v1.1
Tidsramme: Percentage of patients with response at week 12
|
Objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease |
Percentage of patients with response at week 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Median progression-free survival
Tidsramme: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
|
Median overall survival
Tidsramme: From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
|
Median duration of response
Tidsramme: From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
|
Rate of local control of irradiated lesions
Tidsramme: Percentage of stable irradiated lesions at week 12
|
Percentage of stable irradiated lesions at week 12
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Tidsramme: Rate of treatment-related adverse events at week 24
|
Rate of treatment-related adverse events at week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Ilya Tsimafeyeu et al. A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).. J Clin Oncol 44, TPS583-TPS583(2026). DOI:10.1200/JCO.2026.44.7_suppl.TPS583
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Patologiske processer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplastiske processer
- Urologiske neoplasmer
- Karcinom
- Nyre-neoplasmer
- Patologiske tilstande, tegn og symptomer
- Neoplasma Metastase
- Karcinom, nyrecelle
- Undersøgelsesteknikker
- Terapeutik
- Kirurgiske procedurer, operative
- Strålebehandling
- Stereotaksiske teknikker
- Neurokirurgiske procedurer
- pembrolizumab
- Radiokirurgi
- lenvatinib
Andre undersøgelses-id-numre
- LASER
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
In accordance with local legislation
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .